Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06675240

Meditative Neurofeedback for Depression

The goal of this open-label single-arm study is to test a meditative neurofeedback intervention for depressed mood.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Depression - Major Depressive Disorder Anxiety Disorders Behavior Behavioral Symptoms Depression Depression Disorders Digestive System Diseases Feeding and Eating Disorders Gastrointestinal Diseases Mental Disorders Rumination Syndrome

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of California San Diego

La Jolla, California, 92093, United States

Location status: Recruiting

Location contact

Jyoti Mishra

CONTACT

[email protected]

858-232-2855

About this study

The goal of this open-label single-arm study is to test whether a 10-session meditative neurofeedback intervention significantly alleviates depressive symptons as well as improves secondary outcomes of rumination and mindfulness.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • moderate depression per PHQ9 symptom ratings

Exclusion criteria

  • active substance abuse/dependence
  • psychotic disorders
  • bipolar disorder
  • displaying acutely suicidal behaviors

Treatment and study plan

MediNF

Behavioral

Over 10-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided to enhance performance.

Primary outcomes

  1. PHQ9

    Time frame: 8 weeks

    Depression Symptoms on the Patient Health Questionnaire 9-item (PHQ9) scale, min 0 max 27 with lower scores representing better outcome

Secondary outcomes

  1. MAAS

    Time frame: 8 weeks

    Mindfulness on the Mindful Attention Awareness Scale (MAAS), min 6 max 84 with higher scores representing better outcome

  2. RRQ

    Time frame: 8 weeks

    Rumination on the Ruminative Response Questionnaire (RRQ) scale, min 22 max 88 with lower scores representing better outcome

  3. GAD7

    Time frame: 8 weeks

    Anxiety symptoms on the Generalized Anxiety Disorder 7-item (GAD7) scale, min 0 max 21 with lower scores representing better outcome

Study contacts

Contact information is provided by the study sponsor or research team.

Jyoti Mishra, PhD

CONTACT

[email protected]

619-940-4230

Sponsors and collaborators

Lead sponsor

University of California, San Diego

Other

Registry information

Acronym: MediNF

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Nov 5, 2024
Registry last updated
Jan 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.